This Expanded Access Program is intended to facilitate the availability of OFEV to patients suffering from non Idiopathic Pulmonary Fibrosis-Interstitial Lung Disease (non IPF-ILD) with a progressive clinical course despite Standard of Care treatment and for whom no satisfactory authorised alternative therapy exists or who cannot enter a clinical trial.
Drug: OFEV
twice daily
Inclusion Criteria:
None
Exclusion Criteria:
- Patients who are eligible for and can participate in an ongoing non Idiopathic Pulmonary
Fibrosis-Interstitial Lung Disease (non IPF-ILD) study will be excluded from participation
in this Expanded Access Program (EAP).
Banner University Medical Center Tucson
Tucson, Arizona, 85724
Illinois Lung and Critical Care Institute
Peoria, Illinois, 61606
The Lung Research Center, LLC
Chesterfield, Missouri, 63017
Glacier View Research Institute
Kalispell, Montana, 59901
University of Rochester Medical Center
Rochester, New York, 14559
Baylor University Medical Center
Dallas, Texas, 75246
Centra Medical Group
Bedford, Virginia, 24523
Inova Fairfax Medical Campus
Falls Church, Virginia, 22042